The FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL based on phase 3 AMPLIFY data. The fixed 14-month regimen improved progression-free survival versus chemotherapy.
Origin Genomics launches to pursue germline gene editing research despite US prohibitions, while Thermo Fisher completes its $8.88 billion acquisition of Clario Holdings. Lucid Diagnostics reports Q4 revenue growth, and multiple partnerships form across the diagnostics and synthetic biology sectors.
Despite guidelines recommending broad molecular profiling for precision oncology, biomarker testing faces significant implementation barriers including insurance coverage limitations, lengthy turnaround times, and tissue adequacy issues. Studies show most patients lack biomarker results at initial consultation, with up to 43% having insufficient tissue for genotyping in NSCLC cases.
Colorectal cancer diagnoses in people under 50 now account for nearly half of all new cases, prompting specialized treatment programs that use precision medicine and liquid biopsy technology to customize care based on individual tumor genetics.
The AI in genomics market is estimated to grow from USD 1.97 billion in 2026 to USD 317.4 billion by 2040, while the drug discovery informatics market is expected to reach USD 11.18 billion by 2035, driven by machine learning integration and big data analytics.
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Two major partnerships in India's diagnostics sector aim to strengthen precision medicine capabilities. MedGenome acquires majority stake in Medcare Management Services, while SRMIST partners with CORE Diagnostics to train future oncology professionals.
Three interconnected life sciences infrastructure markets are experiencing significant growth driven by precision medicine adoption, increasing clinical trial activity, and advances in genomic diagnostics through 2035.
The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.
The global genomics in cancer care market is projected to grow from $24.39 billion in 2025 to $108.69 billion by 2035, driven by rising cancer incidence, personalized medicine adoption, and next-generation sequencing advances.
